Cite
HARVARD Citation
Ota, S. et al. (2018). Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic‐phase chronic myeloid leukemia. European journal of haematology. pp. 95-105. [Online].